54 results about "Sentinel node" patented technology

Cavity and sentinel lymph node marking 412 devices, marker delivery devices, and methods are disclosed. More particularly, upon insertion into a body, the cavity marking device and method enable one to determine the center, orientation, and periphery of the cavity by radiographic, mammography, echogenic, or other noninvasive imaging techniques. A composition and method are disclosed for locating the sentinel lymph node in a mammalian body to determine if cancerous cells have spread thereto. The composition is preferably a fluid composition consisting of a carrier fluid and some type of contrast agent; alternatively, the contrast agent may itself be a fluid and therefore not need a separate carrier fluid. This composition is capable of (1) deposition in or around a lesion and migration to and accumulation in the associated sentinel node, and (2) remote detection via any number of noninvasive techniques. Also disclosed is a method for remotely detecting the location of a sentinel node by (1) depositing a remotely detectable fluid in or around a lesion for migration to and accumulation in the associated sentinel node and (2) remotely detecting the location of that node with a minimum of trauma and toxicity to the patient. The composition and method may serve to mark a biopsy cavity, as well as mark the sentinel lymph node. The marking methods also may combine any of the features as described with the marking device and delivery device.

Various compositions, methods, and devices are provided that use fluorescent nanoparticles, which can function as markers, indicators, and light sources. The fluorescent nanoparticles can be formed from a fluorophore core surrounded by a biocompatible shell, such as a silica shell. In one embodiment, the fluorescent nanoparticles can be delivered to tissue to mark the tissue, enable identification and location of the tissue, and/or illuminate an area surrounding the tissue. In another embodiment, the fluorescent nanoparticles can be used on a device or implant to locate the device or implant in the body, indicate an orientation of the device or implant, and/or illuminate an area surrounding the device or implant. The fluorescent nanoparticles can also be used to provide a therapeutic effect.

The present invention relates to a device for observing a sentinel lymph node (SLN) in a human body. More particularly, the present invention relates to a device for observing an SLN by detecting near-infrared (NIR) fluorescence caused by a fluorescent material such as indocyanine green (ICG) at the SLN and a method for detecting NIR fluorescence at an SLN. Particularly, in the implementation of a composite image obtained by reproducing a fluorescent material such as ICG and NIR fluorescence emitted by excitation light together with a visible light image, it is possible to detect an SLN with high accuracy through a color contrast method and/or a temporal modulation method using an NIR fluorescence image signal and a visible reflection light image signal.

The invention provides methods for pre- and intra-operatively localizing penile sentinel lymph nodes by injection of fluorescent dyes into penile tumors.

An embodiment of the invention discloses a self-monitoring method and system of a cloud platform. The method includes that each sentinel node adopts regular heart rate detection to monitor monitoring nodes in monitored monitoring services; when main nodes in the monitoring nodes fail, fault transfer is performed on the main nodes which fail. The self-monitoring method and system can monitor the cloud platform itself to enable the services to run normally so as to provide stable and reliable services, so that service performance related to intelligent monitoring of the cloud platform is improved.

The invention provides a specific sentinel lymph node developer drug and a preparation method thereof. A Rituximab antibody is modified and subject to 99mTc marking, so that 99mTc-Rituximab can be obtained, which can combine with a CD20 antigen in the sentinel lymph node to accurately position the sentinel lymph node, thus the sentinel lymph node development of the breast cancer and a biopsy analysis can be performed on breast cancer patients, thereby laying a foundation for establishing a complete set of safe, convenient and effective sentinel lymph node development technology of breast cancer and providing a method and basis for widely clinical application in the coming days.

The invention discloses a Redis master-slave cluster automatic deployment scheme based on Kubernetes, and relates to the technical field of cluster deployment. The configuration file of the redis is transmitted into the Helm installation package in a document flow mode, Helm configuration and starting logic are deployed in consignmap, and in redis-server-statefulset. yaml, initContainers is used to mount various startup scripts to the required pv of the container. The various startup scripts are written to the configmap in a document flow mode. The initContainers uses the command command to start the startup scripts to perform configuration and installation, and perform deployment of master-slave node pod and the sentinel node of the redis in Kubernets.

The invention provides an Evans blue complex which is of formula (I) as shown in the specification. The Evans blue complex structurally comprises two serum albumin combined groups and one macrocyclicpolyamine chelated group NOTA. The invention further provides a marking complex prepared from the Evans blue complex after radionuclide marking. The marked complex provided by the invention is simpleto mark and biological property; biological test results show that the complex has a property of distinguishing sentinel nodes from secondary lymphatic glands. The invention further relates to a preparation method and application of the complex in preparing organ and tissue photographic developers of human beings or animals.

A method and system to predict the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.

The invention discloses a breast cancer sentinel lymph node metastasis prediction method and system and a storage medium, and the method comprises the steps: obtaining a WSI with a label as a training data set, and carrying out the preprocessing, and obtaining an image block set; constructing a WSI classification model; pre-training a feature extractor by using the image block set to obtain a feature vector set; inputting the feature vector set into a prototype clustering module, and extracting a plurality of prototypes through clustering; the breast cancer sentinel lymph node WSI is divided into image blocks, and then the image blocks are input into a feature extractor to extract image block features; matching the image block features with a prototype input feature fusion module, generating a soft distribution histogram, and constructing a feature vector of breast cancer sentinel node WSI; and sending the feature vector of the breast cancer sentinel lymph node WSI into a full connection layer to obtain a WSI classification score, and performing transfer judgment. The method can better solve the problem of micro-metastasis identification while maintaining accurate identification of macro-metastasis, so that breast cancer sentinel lymph node metastasis can be accurately diagnosed.

The invention discloses an application of indocyanine green-rituximab in preparation of a breast cancer sentinel node tracer. When sentinel node biopsy is carried out via an indocyanine green-rituximab coupled specific tracer, since the specific tracer only fluorescently develops the sentinel node and develops no secondary lymph node, the sentinel node does not need to be found along the fluorescently developed lymphatic in the biopsy, the position of the fluorescently developed sentinel node is detected by an infrared fluorescent development system in a surgery, and the sentinel node positioned by fluorescent development is directly dissected and detected after dissecting and dissociating the peripheral tissues of the sentinel node, so as to avoid the situations of leak detection of the sentinel node and fluorescent development pollution of the peripheral tissues.

A detectably labeled porphyrin compound for identifying a sentinel lymph node in patients, particularly those with cancer. A method of identifying a sentinel lymph node, comprising the steps of: injecting the detectably labeled porphyrin compound into a tumor, wherein the porphyrin compound is detectably labeled with a radiolabel which is a γ-emitting radioactive metal; and detecting radioactive emission or a color so as to detect and thereby identify the sentinel lymph node. A method of identifying a sentinel lymph node, comprising the steps of injecting the detectably labeled porphyrin compound into tissue surrounding a tumor, wherein the porphyrin compound is detectably labeled with a non-radioactive metal; and taking a series of magnetic resonance images to identify the sentinel lymph node by viewing the images showing the injected detectably labeled porphyrin compound.

The present invention relates to an optical imaging probe for detecting a sentinel lymph node, which contains a complex of poly-gamma-glutamic acid and an optical imaging dye, and more particularly to an optical imaging probe for detecting a sentinel lymph node, which contains a poly-gamma-glutamic acid/optical imaging dye complex that, when injected subcutaneously in vivo, remains in the sentinel lymph node for a relatively long period of time and has a low tendency to migrate to other lymph nodes. The present invention provides a poly-gamma-glutamic acid/fluorescent dye complex, which contains no radiopharmaceutical and is harmless to the human body. The use of the poly-gamma-glutamic acid/fluorescent dye complex makes it possible to accurately detect the position of a sentinel lymph node in real time without concerns about radioactive contamination.

The invention provides a radionuclide labelled specific sentinel node photographic developer and a preparation method thereof and belongs to the technical field of radioactive drug labeling and nuclear medicine. The radionuclide labelled specific sentinel node photographic developer provided by the invention is prepared by the following steps: by taking a rituximab monoantibody as a parent, separating, purifying and reducing the rituximab monoantibody to obtain a photographic developer precursor; preparing the precursor into a medicine box, wherein the storage life can reach 24 months; carrying out 99mTc radionuclide labeling on the photographic developer precursor to obtain the specific sentinel node photographic developer drug 99mTc-SLN-F, wherein the labeling rate is equal to or greater than 95%. The photographic developer prepared can precisely position the specific sentinel node, the development and biopsy times are not limited, and the photographic developer can develop well in a time interval of 30 minutes to 24 hours after injection. In addition, the photographic developer is low in uptake in a secondary lymph gland and low in retention at injection points. The photographic developer has a good application prospect in treating and diagnosing breast cancer.

The invention relates to a breast cancer area detection method and system for a full-view breast cancer sentinel node pathological image based on a DenseNet network, and the method comprises the steps: 1) obtaining the full-view breast cancer sentinel node pathological image, and manually marking a breast cancer metastasis area; 2) automatically generating a training set and a verification set by using the full-view breast cancer sentinel lymph node pathological image and the labeling result, and training by using a DenseNet network model; 3) predicting a single full-view breast cancer pathology image to obtain a breast cancer probability heat map; 4) calculating breast cancer probability heat maps of the full-view breast cancer pathological images of all the training sets, performing binaryzation and isolated noise suppression, calculating breast cancer feature vectors, and performing training by using a linear classifier; 5) calculating a breast cancer probability heat map for the full-view pathological image of the test set, carrying out binaryzation and isolated noise suppression, calculating a breast cancer feature vector, and predicting the occurrence probability of the breast cancer region, thereby realizing automatic detection of the breast cancer region.

The invention provides a fluorescence-coupled specific sentinel node photographic developer and a preparation method thereof and belongs to the field of preparation of biological medicines. The specific sentinel node photographic developer disclosed by the invention is formed by separating and purifying rituximab coupled with Cy5.5-N-hydroxyl pyrrolidine dione ester (Cy5.5-NHS) which is Cy5.5-SLN-F for short. The photographic developer is convenient to use, stable in performance, as long as 24 months in preservation time, above 95% in labeling rate, high in operability, applicable to noninvasive detection of an infrared-developed sentinel node, low in ingestion by a secondary lymph node, low in retention at an injection point, not limited in development and biopsy time, good in development within 30min to 24 hours after injection, as high as 100% in development rate, higher in safety, low in cost and relatively good in clinical application prospect.

Disclosed is a near-infrared fluorescent imaging agent comprising an indocyanine-based fluorescent dye and a liposome. The near-infrared fluorescent imaging agent of the present invention demonstrates high fluorescence intensity and a long anchoring time in sentinel lymph nodes, thereby making it useful for detecting sentinel lymph nodes in sentinel lymph node navigation surgery. Also disclosed is an indocyanine green derivative that is particularly suitable for use in the near-infrared fluorescent imaging agent of the present invention.